Technical Analysis for PRAX - Praxis Precision Medicines, Inc.

Grade Last Price % Change Price Change
grade C 30.0 -6.25% -2.00
PRAX closed down 6.25 percent on Friday, October 23, 2020, on 71 percent of normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
Historical PRAX trend table...

Date Alert Name Type % Chg
New 52 Week High Strength 0.00%
New 52 Week Closing High Bullish -6.25%
New 52 Week High Strength -6.25%
Multiple of Ten Bullish Other -6.25%
Up 3 Days in a Row Strength -6.25%
New 52 Week Closing High Bullish 0.27%
Multiple of Ten Bearish Other 0.27%
Hot IPO Pullback Bullish Swing Setup 8.11%
New 52 Week Low Weakness 8.11%
Older End-of-Day Gignals for PRAX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% 3 days ago
Down 3% 3 days ago
Reversed from Up 3 days ago
Gap Up Closed 3 days ago
Gap Up Partially Closed 3 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Biopharmaceutical Central Nervous System Disorders Huntington's Disease Major Depressive Disorder Spinal Muscular Atrophy Treatment Of Major Depressive Disorder Antisense RNA Essential Tremor

Is PRAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 32.15
52 Week Low 24.86
Average Volume 323,753
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 0.00
Average True Range 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0
Fundamentals Value
Market Cap 1.1 Billion
Num Shares 36.7 Million
EPS
Price-to-Sales 0.00
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.60
Resistance 3 (R3) 33.92 33.03 33.00
Resistance 2 (R2) 33.03 32.12 32.88 32.80
Resistance 1 (R1) 31.52 31.55 31.08 31.20 32.60
Pivot Point 30.63 30.63 30.41 30.48 30.63
Support 1 (S1) 29.12 29.72 28.68 28.80 27.40
Support 2 (S2) 28.23 29.15 28.08 27.20
Support 3 (S3) 26.72 28.23 27.00
Support 4 (S4) 26.40